National Academies Press: OpenBook

Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary (2010)

Chapter: Appendix A: Workshop Agenda

Get This Book
Visit NAP.edu/10766 to get more information about this book, to buy it in print, or to download it as a free PDF.
« Previous: Glossary
Page 91 Cite
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Save
Cancel

Appendix A
Workshop Agenda

National Cancer Policy Forum

Workshop on Extending the Spectrum of

Precompetitive Collaboration in Oncology Research


The Keck Center of The National Academies

500 Fifth Street, NW, Room 100

Washington, DC 20001


DAY 1: TUESDAY, FEBRUARY 9, 2010

8:00 am

Registration and Continental BreakfastRegistration and Continental Breakfast

8:30 am

Welcome from National Cancer Policy Forum and Overview of the Workshop

John Wagner, M.D., Ph.D., Merck & Co., Inc., Workshop Chair

8:45 am

General Characterization of the Precompetitive Collaboration Environment

Session Chair: John Wagner, M.D., Ph.D., Merck & Co., Inc.

 

Open Innovation Networks Between Academia and Industry

Neal Cohen, M.D., M.P.H., M.S., University of California–San Francisco School of Medicine

 

Overview of Precompetitive Collaboration with Exemplar Models

Jill Altshuler, M.B.A., AltshulerGray
Page 92 Cite
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Save
Cancel

 

Open Access Integrative Bionetworks

Stephen Friend, M.D., Ph.D., Sage Bionetworks

 

PatientsLikeMe

James Heywood

 

Panel Discussion and Audience Polling: 30 Minutes

11:15 am

Break

11:30 am

Precompetitive Collaboration in Science

Session Chair: John Wagner, M.D., Ph.D., Merck & Co., Inc.

 

SEMATECH

William Spencer, Ph.D.

 

Science Commons

Thinh Nguyen, J.D.

 

Panel Discussion: 20 Minutes

12:30 pm

Lunch

1:30 pm

Precompetitive Collaboration in Biomedicine

Session Chair: Stephen Friend, M.D., Ph.D., Sage Bionetworks

 

The Biomarkers Consortium

David Wholley, M. Phil., Foundation for the National Institutes of Health

 

Critical Path Institute

Raymond Woosley, M.D., Ph.D.

 

Breakthrough Innovation

Bernard Munos, M.B.A., Ph.D., Eli Lilly and Company

 

Precompetitive Informatics Initiatives in Drug Discovery

Bryn Williams-Jones, Pfizer
Page 93 Cite
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Save
Cancel

 

Panel Discussion: 30 Minutes

3:45 pm

Break

4:00 pm

Day 1 Concluding Thoughts

Open-Source Science

Karim R. Lakhani, Ph.D., M.S., Harvard Business School

 

Discussion and Audience Polling: 30 minutes

5:00 pm

Adjourn Day 1

DAY 2: WEDNESDAY, FEBRUARY 10, 2010

8:00 am

Registration and Continental Breakfast

8:30 am

Thoughts on Day 1 and Report Back from Dinner Discussion

8:45 am

Precompetitive Collaboration in Oncology

Session Chair: Stephen Eck, M.D., Ph.D., Eli Lilly and Company

 

I-SPY 2 TRIAL

Laura Esserman, M.D., M.B.A., UCSF Carol Franc Buck Breast Care Center

 

The Cancer Genome Atlas

Joseph Vockley, Ph.D., National Cancer Institute

 

Merck, AstraZeneca Drug Combination

Pearl Huang, Ph.D., Merck & Co., Inc.

 

CEO Roundtable on Cancer’s Life Sciences Consortium

Gregory Curt, M.D., AstraZeneca
Page 94 Cite
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Save
Cancel

 

Imaging Studies

Gary Kelloff, M.D., National Cancer Institute1

 

Panel Discussion: 30 Minutes

11:30 am

Break—Pick Up Boxed Lunches and Return for Final Session

11:45 am

Lessons Learned and Future Directions for Precompetitive Collaboration in Oncology

Session Chair: John Wagner, M.D., Ph.D., Merck & Co., Inc.

 

Opening Remarks

Mark McClellan, M.D., Ph.D., Brookings Institution’s Engelberg Center for Health Care Reform

 

Panelists:

Jill Altshuler, M.B.A., AltshulerGray

Neal Cohen, M.D., M.P.H., M.S., University of California–San Francisco School of Medicine

Stephen Eck, M.D., Ph.D., Eli Lilly and Company

Mark McClellan, M.D., Ph.D., Brookings Institution’s Engelberg Center for Health Care Reform

Raymond Woosley, M.D., Ph.D., Critical Path Institute

1:30 pm

Adjourn Day 2

1

 Due to the snowstorm, Dr. Kelloff was unable to present at the workshop. However, his presentation slides were included in the workshop briefing materials.
Page 91 Cite
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Save
Cancel
Page 91
Page 92 Cite
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Save
Cancel
Page 92
Page 93 Cite
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Save
Cancel
Page 93
Page 94 Cite
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Save
Cancel
Page 94
Next: Appendix B: Polling Results »
Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary Get This Book
×
Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary
Buy Paperback | $41.00 Buy Ebook | $32.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation.

Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development. While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations.

Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings.

READ FREE ONLINE

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!